Wave Life Sciences Ltd. logo WVE - Wave Life Sciences Ltd.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 23
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $26.38 DETAILS
HIGH: $43.00
LOW: $13.00
MEDIAN: $28.00
CONSENSUS: $26.38
UPSIDE: 313.48%

Stock News

Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data

Wave Life Sciences: 'Strong Buy' On DMD NDA Filing WVE-N531 And Released AATD Data

Wave Life Sciences Ltd. retains a Strong Buy rating, driven by near-term Accelerated Approval catalysts for WVE-N531 and WVE-006. The company is on track to file an NDA for WVE-N531 in DMD exon 53 skipping in 2026, targeting approval based on dystrophin production and functional testing. Recent phase 1b/2a data for WVE-006 in AATD showed up to 70.5% Z-AAT reduction with multi-dosing, with key FDA feedback and 600 mg multi-dose data expected in mid/late 2026.

May 20, 2026 09:21 AM • seekingalpha.com
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Alibaba, Boston Scientific, Brown-Forman, Charter Communications, Franklin Resources, Spotify, T-Mobile, and More

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Alibaba, Boston Scientific, Brown-Forman, Charter Communications, Franklin Resources, Spotify, T-Mobile, and More

Pre-Market Stock Futures: Futures are trading modestly higher as we hit the midweek mark, and some buyers' exhaustion likely played a role, as all the major indices finished lower on Tuesday. This comes after both the Nasdaq and the S&P 500 hit all-time highs once again earlier this week. The combination of mixed earnings, some... Here Are Wednesday's Top Wall Street Analyst Research Calls: Alibaba, Boston Scientific, Brown-Forman, Charter Communications, Franklin Resources, Spotify, T-Mobile, and More

Apr 29, 2026 03:57 AM • 247wallst.com
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company's first quarter 2026 financial results and provide business updates.

Apr 22, 2026 04:30 AM • globenewswire.com
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, is seeking shareholders' and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the “Scheme of Arrangement”), in order to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the “Redomiciliation”).

Apr 21, 2026 12:01 PM • globenewswire.com
Wave Life Sciences Announces Proposed Redomiciliation to the United States

Wave Life Sciences Announces Proposed Redomiciliation to the United States

CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that its board of directors has unanimously approved a plan to redomicile the parent company of the Wave Life Sciences group of companies from Singapore to the United States (the Redomiciliation).

Apr 15, 2026 12:01 PM • globenewswire.com
Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Expand NASDAQ: WVE Wave Life Sciences Today's Change (-49.84%) $-6.13 Current Price $6.17 Key Data Points Market Cap $2.3B Day's Range $5.04 - $6.48 52wk Range $5.04 - $21.73 Volume 1.5M Avg Vol 3.3M Gross Margin 79.28% Wave Life Sciences (WVE 49.84%), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.

Mar 26, 2026 01:30 PM • fool.com

Price Targets